Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Classical hematology 2

Conditions

Neoplasm Metastasis 32Multiple Myeloma 23Leukemia, Myeloid, Acute 23Lymphoma 17Colorectal Neoplasms 16Breast Neoplasms 14Pancreatic Neoplasms 12Myelodysplastic Syndromes 12Triple Negative Breast Neoplasms 10Sarcoma 9Prostatic Neoplasms 9Leukemia, Lymphocytic, Chronic, B-Cell 9Burkitt Lymphoma 9Ovarian Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, T-Cell 7Glioma 7Endometrial Neoplasms 7Neuroblastoma 6Melanoma 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Carcinoma, Renal Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Myeloproliferative Disorders 5Lymphoma, Follicular 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5Central Nervous System Neoplasms 5

Interventions

Whole-Body Irradiation 5Cyclophosphamide 5fludarabine phosphate 4Busulfan 4Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Melphalan 3Cyclosporine 3venetoclax 2fludarabine 2Tacrolimus 2Specimen Handling 2Methotrexate 2Etoposide 2Biopsy 2Azacitidine 2Antilymphocyte Serum 2merphos 1ivosidenib 1decitabine and cedazuridine drug combination 1Vorinostat 1Thiotepa 1TAK-243 1Sirolimus 1Rituximab 1Lenalidomide 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Clofarabine 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Biopsy × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡